Prevep, Inc.

PrevEp is a biopharmaceutical company developing epilepsy treatments, including an intranasal seletracetam spray for preemptive seizure treatment, combination therapies for epilepsy prevention following traumatic brain injury and stroke, and an intravenous topiramate formulation for neonatal seizures. The company was founded by researchers who discovered levetiracetam (Keppra) and ezogabine, and operates multiple drug development programs currently in preclinical and Phase 1 stages.